MeiraGTx Holdings plc Weighted Average Number of Shares Outstanding, Basic and Diluted
MeiraGTx Holdings plc (MGTX) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 43.97 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-11
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 43.97M shares, a 20.07% increase year-over-year.
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 40.08M shares, a 10.36% increase year-over-year.
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 37.22M shares, a 7.38% increase year-over-year.
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 36.97M shares, a 12.62% increase year-over-year.
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 37.72M shares, a 13.76% increase from fiscal 2019.
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 33.16M shares, a 75.01% increase from fiscal 2018.
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 18.95M shares, a 121.04% increase from fiscal 2017.
- MeiraGTx Holdings plc weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 8.57M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | 43.97M shares 10-Q · filed 2021-05-11 | 42.03M shares derived: average of 2 quarters · filed 2021-05-11 | 40.42M shares derived: average of 3 quarters · filed 2021-05-11 | 39.56M shares derived: average of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 40.08M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 38.65M shares derived: average of 2 quarters · filed 2021-03-11 | 38.09M shares derived: average of 3 quarters · filed 2021-03-11 | 37.72M shares 10-K · filed 2021-03-11 |
| 2020-09-30 | 37.22M shares 10-Q · filed 2020-11-05 | 37.10M shares derived: average of 2 quarters · filed 2020-11-05 | 36.94M shares 10-Q · filed 2020-11-05 | 36.78M shares derived: average of 4 quarters · filed 2021-05-11 |
| 2020-06-30 | 36.97M shares 10-Q · filed 2020-08-06 | 36.80M shares 10-Q · filed 2020-08-06 | 36.64M shares derived: average of 3 quarters · filed 2021-05-11 | 36.14M shares derived: average of 4 quarters · filed 2021-05-11 |
| 2020-03-31 | 36.62M shares 10-Q · filed 2021-05-11 | 36.47M shares derived: average of 2 quarters · filed 2021-05-11 | 35.87M shares derived: average of 3 quarters · filed 2021-05-11 | 35.11M shares derived: average of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | 36.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 35.49M shares derived: average of 2 quarters · filed 2021-03-11 | 34.60M shares derived: average of 3 quarters · filed 2021-03-11 | 33.16M shares 10-K · filed 2021-03-11 |
| 2019-09-30 | 34.66M shares 10-Q · filed 2020-11-05 | 33.75M shares derived: average of 2 quarters · filed 2020-11-05 | 32.11M shares 10-Q · filed 2020-11-05 | 30.75M shares derived: average of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | 32.83M shares 10-Q · filed 2020-08-06 | 30.81M shares 10-Q · filed 2020-08-06 | 29.44M shares derived: average of 3 quarters · filed 2020-08-06 | 28.67M shares derived: average of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | 28.78M shares 10-Q · filed 2020-05-07 | 27.75M shares derived: average of 2 quarters · filed 2020-05-07 | 27.28M shares derived: average of 3 quarters · filed 2020-05-07 | 23.86M shares derived: average of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | 26.73M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | 26.53M shares derived: average of 2 quarters · filed 2020-03-11 | 22.23M shares derived: average of 3 quarters · filed 2020-03-11 | 18.95M shares 10-K · filed 2020-03-11 |
| 2018-09-30 | 26.34M shares 10-Q · filed 2019-11-07 | 19.98M shares derived: average of 2 quarters · filed 2019-11-07 | 16.36M shares 10-Q · filed 2019-11-07 | 14.39M shares derived: average of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | 13.61M shares 10-Q · filed 2019-08-07 | 11.28M shares 10-Q · filed 2019-08-07 | 10.41M shares derived: average of 3 quarters · filed 2019-08-07 | 9.96M shares derived: average of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | 8.93M shares 10-Q · filed 2019-05-14 | 8.80M shares derived: average of 2 quarters · filed 2019-05-14 | 8.74M shares derived: average of 3 quarters · filed 2019-05-14 | 8.68M shares derived: average of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | 8.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | 8.64M shares derived: average of 2 quarters · filed 2019-03-26 | 8.60M shares derived: average of 3 quarters · filed 2019-03-26 | 8.57M shares 10-K · filed 2019-03-26 |
| 2017-09-30 | 8.61M shares 10-Q · filed 2018-11-08 | 8.56M shares derived: average of 2 quarters · filed 2018-11-08 | 8.54M shares 10-Q · filed 2018-11-08 | |
| 2017-06-30 | 8.51M shares 10-Q · filed 2018-08-08 | 8.55M shares 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |